1. Home
  2. NTHI vs GECC Comparison

NTHI vs GECC Comparison

Compare NTHI & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTHI
  • GECC
  • Stock Information
  • Founded
  • NTHI 2008
  • GECC 2016
  • Country
  • NTHI United States
  • GECC United States
  • Employees
  • NTHI N/A
  • GECC N/A
  • Industry
  • NTHI Biotechnology: Pharmaceutical Preparations
  • GECC Finance: Consumer Services
  • Sector
  • NTHI Health Care
  • GECC Finance
  • Exchange
  • NTHI Nasdaq
  • GECC Nasdaq
  • Market Cap
  • NTHI 110.9M
  • GECC 127.9M
  • IPO Year
  • NTHI N/A
  • GECC N/A
  • Fundamental
  • Price
  • NTHI $5.12
  • GECC $11.09
  • Analyst Decision
  • NTHI
  • GECC
  • Analyst Count
  • NTHI 0
  • GECC 0
  • Target Price
  • NTHI N/A
  • GECC N/A
  • AVG Volume (30 Days)
  • NTHI 320.0K
  • GECC 28.5K
  • Earning Date
  • NTHI 01-01-0001
  • GECC 08-04-2025
  • Dividend Yield
  • NTHI N/A
  • GECC 13.80%
  • EPS Growth
  • NTHI N/A
  • GECC 29.91
  • EPS
  • NTHI N/A
  • GECC 1.58
  • Revenue
  • NTHI $79,990.00
  • GECC $47,638,000.00
  • Revenue This Year
  • NTHI N/A
  • GECC $32.09
  • Revenue Next Year
  • NTHI N/A
  • GECC $0.51
  • P/E Ratio
  • NTHI N/A
  • GECC $7.00
  • Revenue Growth
  • NTHI 13.52
  • GECC 29.12
  • 52 Week Low
  • NTHI $3.20
  • GECC $8.87
  • 52 Week High
  • NTHI $25.00
  • GECC $11.39
  • Technical
  • Relative Strength Index (RSI)
  • NTHI N/A
  • GECC 60.89
  • Support Level
  • NTHI N/A
  • GECC $10.89
  • Resistance Level
  • NTHI N/A
  • GECC $11.14
  • Average True Range (ATR)
  • NTHI 0.00
  • GECC 0.09
  • MACD
  • NTHI 0.00
  • GECC 0.00
  • Stochastic Oscillator
  • NTHI 0.00
  • GECC 79.31

About NTHI NeOnc Technologies Holdings Inc. Common Stock

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.

Share on Social Networks: